• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Hospitalisation among vaccine breakthrough COVID-19 infections.

作者信息

Juthani Prerak V, Gupta Akash, Borges Kelly A, Price Christina C, Lee Alfred I, Won Christine H, Chun Hyung J

机构信息

Department of Internal Medicine, Yale School of Medicine, New Haven, CT 06511, USA.

Yale Center for Clinical Investigation, Yale School of Medicine, New Haven, CT 06511, USA.

出版信息

Lancet Infect Dis. 2021 Nov;21(11):1485-1486. doi: 10.1016/S1473-3099(21)00558-2. Epub 2021 Sep 7.

DOI:10.1016/S1473-3099(21)00558-2
PMID:34506735
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8423430/
Abstract
摘要

相似文献

1
Hospitalisation among vaccine breakthrough COVID-19 infections.疫苗突破性新冠病毒感染导致的住院情况。
Lancet Infect Dis. 2021 Nov;21(11):1485-1486. doi: 10.1016/S1473-3099(21)00558-2. Epub 2021 Sep 7.
2
Effectiveness of COVID-19 vaccines in preventing SARS-CoV-2 infection and hospitalisation, Navarre, Spain, January to April 2021.2021 年 1 月至 4 月，西班牙纳瓦拉地区 COVID-19 疫苗预防 SARS-CoV-2 感染和住院的有效性。
Euro Surveill. 2021 May;26(21). doi: 10.2807/1560-7917.ES.2021.26.21.2100438.
3
The effectiveness of mRNA vaccines to prevent SARS-CoV-2 infection and hospitalisation for COVID-19 according to the time elapsed since their administration in health professionals in the Valencian Autonomous Community (Spain).根据在西班牙瓦伦西亚自治区接种疫苗后时间的推移，mRNA 疫苗在预防卫生专业人员中 SARS-CoV-2 感染和 COVID-19 住院的有效性。
Prev Med. 2022 Oct;163:107237. doi: 10.1016/j.ypmed.2022.107237. Epub 2022 Aug 31.
4
Breakthrough SARS-CoV-2 infections after COVID-19 immunization.突破性 SARS-CoV-2 感染 COVID-19 免疫后。
J Investig Med. 2022 Aug;70(6):1429-1432. doi: 10.1136/jim-2021-002131. Epub 2022 Jun 29.
5
Age and product dependent vaccine effectiveness against SARS-CoV-2 infection and hospitalisation among adults in Norway: a national cohort study, July-November 2021.2021 年 7 月至 11 月期间，挪威成年人中针对 SARS-CoV-2 感染和住院的年龄和产品依赖性疫苗有效性：一项全国队列研究。
BMC Med. 2022 Sep 2;20(1):278. doi: 10.1186/s12916-022-02480-4.
6
SARS-CoV-2 Breakthrough Infections after introduction of 4 COVID-19 Vaccines, South Korea, 2021.2021 年韩国引入 4 种 COVID-19 疫苗后发生的 SARS-CoV-2 突破感染。
Emerg Infect Dis. 2022 Mar;28(3):753-756. doi: 10.3201/eid2803.212210.
7
SARS-CoV-2 vaccine breakthrough infection following a previous infection in a healthcare worker.一名医护人员在先前感染后出现的新型冠状病毒2型疫苗突破性感染。
J Infect. 2022 Mar;84(3):418-467. doi: 10.1016/j.jinf.2021.10.008. Epub 2021 Oct 19.
8
Vaccine Breakthrough Infections of SARS-Cov-2: A Case Report.SARS-CoV-2 疫苗突破性感染：一例病例报告。
Ethiop J Health Sci. 2022 Jan;32(1):201-204. doi: 10.4314/ejhs.v32i1.20.
9
Defining SARS-CoV-2 breakthrough infection needing hospitalization in mass vaccination era: from disease-centered to patient-centered care.定义大规模疫苗接种时代需要住院治疗的 SARS-CoV-2 突破性感染：从以疾病为中心到以患者为中心的护理。
Acta Biomed. 2022 May 11;93(2):e2022182. doi: 10.23750/abm.v93i2.12717.
10
Breakthrough SARS-CoV-2 infections after COVID-19 mRNA vaccination in MS patients on disease modifying therapies during the Delta and the Omicron waves in Italy.在意大利 Delta 和奥密克戎变异株流行期间，接受疾病修正治疗的多发性硬化症患者在感染 COVID-19 后突破性感染 SARS-CoV-2。
EBioMedicine. 2022 Jun;80:104042. doi: 10.1016/j.ebiom.2022.104042. Epub 2022 May 5.

引用本文的文献

1
SARS-CoV-2 Vaccines and Multiple Sclerosis: An Update.严重急性呼吸综合征冠状病毒2型疫苗与多发性硬化症：最新进展
Neurol Neuroimmunol Neuroinflamm. 2025 May;12(3):e200393. doi: 10.1212/NXI.0000000000200393. Epub 2025 Apr 25.
2
Cost-Effectiveness Analysis of Molnupiravir Versus Best Supportive Care for the Treatment of Outpatient COVID-19 in High-Risk Older Adults in Japan.莫努匹拉韦与最佳支持治疗对日本高危老年门诊COVID-19患者治疗的成本效益分析
Pharmacoecon Open. 2025 Apr 23. doi: 10.1007/s41669-025-00578-y.
3
Immune cell populations and induced immune responses at admission in patients hospitalized with vaccine breakthrough SARS-CoV-2 infections.疫苗突破性 SARS-CoV-2 感染住院患者入院时的免疫细胞群体和诱导的免疫反应。
Front Immunol. 2024 Jun 5;15:1360843. doi: 10.3389/fimmu.2024.1360843. eCollection 2024.
4
Vaccination status and disease severity of COVID-19 in different phases of the pandemic.疫苗接种状况和大流行不同阶段 COVID-19 疾病严重程度。
Hum Vaccin Immunother. 2024 Dec 31;20(1):2353491. doi: 10.1080/21645515.2024.2353491. Epub 2024 Jun 4.
5
Data-driven scalable pipeline using national agent-based models for real-time pandemic response and decision support.使用基于智能体的国家模型进行实时疫情应对和决策支持的数据驱动可扩展流程。
Int J High Perform Comput Appl. 2023 Jan;37(1):4-27. doi: 10.1177/10943420221127034.
6
Impact of vaccination on COVID-19 severity during the second wave in Brunei Darussalam, 2021.2021 年文莱达鲁萨兰国第二波疫情期间疫苗接种对 COVID-19 严重程度的影响。
Western Pac Surveill Response J. 2024 Mar 25;15(1):1-11. doi: 10.5365/wpsar.2024.15.1.992. eCollection 2024 Jan-Mar.
7
Epidemiology, clinical features and outcomes of hospitalized patients with COVID-19 by vaccination status: a multicenter historical cohort study.接种疫苗状况对 COVID-19 住院患者的流行病学、临床特征和结局的影响：一项多中心历史队列研究。
Virol J. 2024 Mar 21;21(1):71. doi: 10.1186/s12985-024-02325-x.
8
Dietary habits, traveling and the living situation potentially influence the susceptibility to SARS-CoV-2 infection: results from healthcare workers participating in the RisCoin Study.饮食习惯、旅行和生活状况可能会影响感染 SARS-CoV-2 的易感性：参与 RisCoin 研究的医护人员的研究结果。
Infection. 2024 Aug;52(4):1425-1437. doi: 10.1007/s15010-024-02201-4. Epub 2024 Mar 4.
9
COVID-19 in cancer patients: The impact of vaccination on outcomes early in the pandemic.癌症患者中的 COVID-19：大流行早期疫苗接种对结局的影响。
Cancer Med. 2023 Dec;12(24):22006-22022. doi: 10.1002/cam4.6781. Epub 2023 Dec 8.
10
Nirmatrelvir combined with ritonavir for preventing and treating COVID-19.奈玛特韦/利托那韦片用于 COVID-19 的预防和治疗。
Cochrane Database Syst Rev. 2023 Nov 30;11(11):CD015395. doi: 10.1002/14651858.CD015395.pub3.

本文引用的文献

1
Vaccine effectiveness of the first dose of ChAdOx1 nCoV-19 and BNT162b2 against SARS-CoV-2 infection in residents of long-term care facilities in England (VIVALDI): a prospective cohort study.英格兰长期护理机构居民中 ChAdOx1 nCoV-19 与 BNT162b2 疫苗首针接种对 SARS-CoV-2 感染的疫苗有效性（VIVALDI）：一项前瞻性队列研究。
Lancet Infect Dis. 2021 Nov;21(11):1529-1538. doi: 10.1016/S1473-3099(21)00289-9. Epub 2021 Jun 23.
2
SARS-CoV-2 Infection after Vaccination in Health Care Workers in California.加利福尼亚州医护人员接种疫苗后感染新冠病毒
N Engl J Med. 2021 May 6;384(18):1774-1775. doi: 10.1056/NEJMc2101927. Epub 2021 Mar 23.
3
BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting.BNT162b2 mRNA 新冠病毒疫苗在全国大规模疫苗接种环境中的效果。
N Engl J Med. 2021 Apr 15;384(15):1412-1423. doi: 10.1056/NEJMoa2101765. Epub 2021 Feb 24.
4
Interim Results of a Phase 1-2a Trial of Ad26.COV2.S Covid-19 Vaccine.Ad26.COV2.S 新冠疫苗 1/2a 期临床试验的中期结果。
N Engl J Med. 2021 May 13;384(19):1824-1835. doi: 10.1056/NEJMoa2034201. Epub 2021 Jan 13.
5
Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine.mRNA-1273 新型冠状病毒疫苗的有效性和安全性。
N Engl J Med. 2021 Feb 4;384(5):403-416. doi: 10.1056/NEJMoa2035389. Epub 2020 Dec 30.